Kaposi's sarcoma (KS) is a lymphangioproliferative disorder associated with Human herpesvirus 8 (HHV8) infection. Four clinical subtypes are recognized: classic, endemic, epidemic (HIV-related) and iatrogenic. KS diagnosis is based on clinical features, histopathological assessment, and HHV8 serology. Classic KS is usually skin-limited and has a chronic course, while the iatrogenic variant may show mucosal, nodal or visceral involvement. Clinical staging is fundamental to guide the management. Localized disease may be treated with different local therapies, even if there are no randomized trials comparing these different modalities. Aggressive, disseminated KS and cases with visceral involvement usually require systemic chemotherapy, most commonly vinblastine, bleomycin or paclitaxel. Iatrogenic KS needs immunosuppression tapering/ withdrawal and, if possible, switch to m-TOR inhibitors in post-transplant KS. The present work by a panel of Italian experts provides guidelines on KS diagnosis and management based on a critical review of the literature and a long and extensive personal experience.

Diagnosis and treatment of classic and iatrogenic Kaposi's sarcoma: Italian recommendations / L. Brambilla, G. Genovese, E. Berti, K. Peris, F. Rongioletti, G. Micali, F. Ayala, S. Della Bella, R. Mancuso, P. Calzavara Pinton, A. Tourlaki. - In: ITALIAN JOURNAL OF DERMATOLOGY AND VENEREOLOGY. - ISSN 2784-8671. - 156:3(2021), pp. 356-365. [10.23736/S2784-8671.20.06703-6]

Diagnosis and treatment of classic and iatrogenic Kaposi's sarcoma: Italian recommendations

G. Genovese;E. Berti;S. Della Bella;A. Tourlaki
Ultimo
2021

Abstract

Kaposi's sarcoma (KS) is a lymphangioproliferative disorder associated with Human herpesvirus 8 (HHV8) infection. Four clinical subtypes are recognized: classic, endemic, epidemic (HIV-related) and iatrogenic. KS diagnosis is based on clinical features, histopathological assessment, and HHV8 serology. Classic KS is usually skin-limited and has a chronic course, while the iatrogenic variant may show mucosal, nodal or visceral involvement. Clinical staging is fundamental to guide the management. Localized disease may be treated with different local therapies, even if there are no randomized trials comparing these different modalities. Aggressive, disseminated KS and cases with visceral involvement usually require systemic chemotherapy, most commonly vinblastine, bleomycin or paclitaxel. Iatrogenic KS needs immunosuppression tapering/ withdrawal and, if possible, switch to m-TOR inhibitors in post-transplant KS. The present work by a panel of Italian experts provides guidelines on KS diagnosis and management based on a critical review of the literature and a long and extensive personal experience.
Diagnosis; Herpesvirus 8, human; Kaposi; Sarcoma; Humans; Iatrogenic Disease; Italy; Acquired Immunodeficiency Syndrome; Sarcoma, Kaposi; Skin Neoplasms
Settore MED/04 - Patologia Generale
Settore MED/35 - Malattie Cutanee e Veneree
2021
Article (author)
File in questo prodotto:
File Dimensione Formato  
R23Y2021N03A0356.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 451.5 kB
Formato Adobe PDF
451.5 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/898722
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 16
social impact